

All of Us Advisory Panel Meeting



December 09, 2021



Agenda

Time	Торіс	Presenter	
11:00 a.m. – 11:30 a.m	Program Update (Open session)	Josh Denny	
11:30 a.m. – 11:35 a.m.	Closed Session Starts		

Open session will be recorded.



2021 Updates

All of Us Senior Leadership Additions



Karriem Watson, DHSc Chief Engagement Officer



Holly Garriock, PhD Chief Cohort Development Officer



Geoffrey Ginsburg, MD, PhD Chief Medical and Scientific Officer Designee



Martin Mendoza, PhD Director of Health Equity



Andrea Ramirez, MD, MS Senior Advisor to CEO

By the end of 2021, we will:

1) Restart enrollment following COVID-19

We will reestablish a national infrastructure enrolling 3k core participants per week.

2) Enable Participant Enrollment for Anyone, Anywhere

We *will be comfortable with* a national ad campaign that will result in enrollment, biospecimen donation, and data collection from anyone, anywhere.*

3) Enhance Participant Value

Participants will perceive All of Us as a product that provides them value.


4) Establish a Diversity of Researchers and Research

We will have grown to an initial "critical mass" of diverse researchers and research that will return value to researchers and participants.

When there are resource conflicts, we will use this priority order to resolve them.

*not children, incarcerated, on tribal lands, or decisionally impaired


Program Enrollment During COVID-19 Pandemic (As of December 7, 2021)



https://www.researchallofus.org/


241 clinic sites in 20 states are activated

Status of the Program




https://www.researchallofus.org/data-tools/data-snapshots

Over 80% of *All of Us* participants are underrepresented in biomedical research



Focused on Increased Participant Engagement

- Increased outreach and capabilities to facilitate participant continued engagement
- Increased % of participants with EHRs from 55% to 79%



Participants completing new activities within last 18 months

Completed Tribal Consultation; Focus on Next Steps

Tribal Consultation Final Report Published March 2021



Forming Tribal Partnerships

Forming collaborative agreements with Tribal Nations to respect tribal sovereignty and research regulations

— I	
_	
_	
_	

Providing Guidance and Resources

- Added information about consultation for participants in Portal
- Clarifying engagement with urban-based AI/AN individuals



Developing Training and Resources for Researchers


 Promoting cultural sensitivity and emphasizing avoidance of stigmatizing research




Integrating AI/AN Data in the Research Hub

- Data from Al/AN individuals will be included in 2022
- Tribal affiliation will not be displayed without an agreement with the Tribe

Returning Genomic Results to Participants and More to Come



Whole Genome Sequences generated



Non-Health Genetic Traits Non-Health Genetic Traits Genetic Ancestry Currently returning to participants >64,000 participants have viewed traits or ancestry

Health-Related Genetic Traits



	P	G	x
Ξ		_	=
9			

Hereditary Disease Risk Medicine and Your Health

Launching in mid-2022

Launched a Focused Social Determinants of Health Survey

- Launched on 11/04/2021
- Ties in with our work with UNITE
- >59,000 (15.6%) participants have completed, with more engagement efforts planned
- 81 questions including branching logic in one question
- Collaborated with experts from NIMHD, NHLBI, NIDDK, NICHD, OBSSR, ORWH, UCSF, Harvard and UC Berkeley



Deliver an End-to-End Genetics Experience for Health-Related Genomics Results *Expected mid-2022*

SEARCH PROGRAM	JANE DOE DOB: May 25, 1977 ID: 123456	Specimen: Blood Barcode: 223-234234 2343 Collected: September 15, 2018 Report date: Cottober 2, 2019	(
	Medicine and yo Our genes affect h to medicine.	ur DNA		RESEARCH RESULT - Your doctor will need to confi	irm this result with a clinical test before using it in your care.
es affect how we ond to medicine in y different ways	RESEARCH PROGRAM	JANE DDE Specimen: Blood DOB: May 23,1077 Barceder: 223 24234 2343 DB: 124456 Collection 15,201 Report date: Collection 25,000 Report date: Collection 25,0		Confirm these results with a clinical DNA for You are eligible for a free clinical DNA test. Because to research results, a clinical DNA test is needed for you to use this information in your care.	these are Get Started
at is this kind of rmation used for?	<u> </u>	Your Result: Something very important for your health was found in your BRCA1 gene		Doctors and health care providers sometimes use DNA information in a patient's care. When deciding how often to check you for cancer or other diseases, doctors also think about other things, like your age or whether anyone else in your family had cancer or other diseases.	
	What does this mean?	 This result means that you are more likely than other people to get certain types of cancer. It does not mean that you have certain types of cance It does not mean that you will definitely est certain 		in your formy had cancer of ouries calebrase	
IPORTANT!		 to be included that you will define you will define you will be important types of cancer. This result is important and should not be ignored. 		If your sex assigned at birth was female	If your sex assigned at birth was male
hare this port with our doctor.	IMPORTANT! Share this	 This report comes from a research program so it is a research result. Your doctor will need to confirm these results with a clinical genetics test before using them in your care. Do not change your medical care before this result i 		Why does this matter? If this result is confirmed by a clinical DNA test, your doctor might talk with you about: ¹ Self-exams	Why does this matter? If this result is confirmed by a clinical DNA test, your doctor might talk with you about: ¹ Self-exams
ter: XXXXXX, CLIA #XXXXXXXX Ineqther: XXXXXXX	report with your doctor.	 confirmed by your doctor. Results provided are from an investigational device An "investigational device" is a device that is the subject of a clinical study. 			
	The BRCA1 gene	Women and men who have this result in the BRCAI ger have a higher chance of developing certain cancers in th lifetime compared to someone without this result. Won are at higher risk for breast cancer and ovarian cancer. They may also have a higher risk of pancreatic cancer. I are at higher risk for male breast cancer and pancreatic cancer. They may also have a higher risk of postate can	n	All Hereditary Disease Risk results will be returned through a genetic counselor, and <u>we will offer</u> <u>confirmatory clinical genetic testing</u> .	
	Genome Center: 30000, CLIA #XX00000	Hereditary Disease Risk Report: DNA and the risk for some	395 17		

All of Us COVID-19 Serology Study in Partnership with NCI, FNL, and NIAID

Clinical Infectious Diseases

MAJOR ARTICLE


ETIDSA hivma hivmedicine association

Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in *All of Us* Research Program Participants, 2 January to 18 March 2020

Keri N. Althoff,¹² David J. Schlueter,³ Hoda Anton-Culver,⁴ James Cherry,⁵ Joshua C. Denny,² Isaac Thomsen,⁶ Elizabeth W. Karlson,⁷ Fiona P. Havers,⁸ Mine S. Cicek,⁹ Stephen N. Thibodeau,⁹ Ligia A. Pinto,¹⁰ Douglas Lowy,⁵ Bradley A. Malin,⁶ Lucila Ohno-Machado,¹¹ Carolyn Williams,¹² David Goldstein,¹³ Aymone Kouame,⁶ Andrea Ramirez,² Adrienne Roman,⁶ Norman E. Sharpless,⁵ Kelly A. Gebo,^{14,a} and Sheri D. Schully^{2,a}; on behalf of the *All of Us* Research Program



- 9 cases in 5 states (IL, MA, WI, PA, MS) in 24,079 tested samples
 - 7 cases earlier than previously known in those states
 - Earliest case was January 7, 2020
- Results were returned to participants






Launch of the Researcher Workbench: Registered Tier


Researcher Workbench Launched on May 27, 2020

- Approved researchers have "passport access" to Workbench data – No individual project or IRB approval needed
- New researchers can start doing research in as little as 2 hours after application



ResearchAllofUs.org

Since the Launch of Researcher Workbench we have Expanded the Data




Plus: ~90k whole genomes + ~165K arrays coming spring 2022


Researcher Workbench: By the Numbers (Since Launch in May 2020)

Research on the Researcher Workbench 1300 +900+ 45+ Registered Active **Publications** Researchers Projects using All of Us Institutional Agreements WA ND MT 6 MN More than 280 Δ SD W OR ID 2 a registered institutions 1 M WY Δ IA 18 NE 4 OH IN NV UT **23%** are Historically CO 13 KS MO 3 5 MD 115 2 CA Black Colleges and 5 33 ОК NC Universities, AR AZ NM 1 'ns 5 2 **Hispanic Serving** GA TX Institutions, or 26 Non-Profits 10

March 2021, Dr. Patrick Wu Defends His PhD Dissertation: Repurposing drugs using gene expression signatures and EHR data



One Week Later: He emails me this figure from All of Us...



Upcoming Controlled Tier Release by Spring 2022

More granular data

- Expanded sociodemographic data
- Dates of services
- Expanded COVID-19 diagnoses and vaccination information and more COPE survey data

New data types

- Derived social determinants of health
 - Socioeconomic statistics (SES) factors derived from census clusters and American Community Survey (ACS)
- Genomics: Expected ~90,000 WGS + ~165,000 arrays





Individual Biospecimen and Participant Data (Available in the future)

Controlled Tier (Available in the future) <u>No obvious PII</u>. Genomics, Clinical Narrative data Data Linkages, Other Data Types

Registered Tier (Available Now) Surveys, EHRs, Physical Measurements Exceeds HIPAA Safe Harbor Standards

Public Tier (Available Now) Summary Statistics Aggregate Counts





All of Us Data Roadmap

